select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Obsessive-Compulsive Disorder-Pipeline Review, H1 2015

Obsessive-Compulsive Disorder-Pipeline Review, H1 2015

  • Products Id :- GMDHC6064IDB
  • |
  • Pages: 61
  • |
  • January 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Obsessive-Compulsive Disorder-Pipeline Review, H1 2015


Global Markets Direct's, 'Obsessive-Compulsive Disorder-Pipeline Review, H1 2015', provides an overview of the Obsessive-Compulsive Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obsessive-Compulsive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obsessive-Compulsive Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Obsessive-Compulsive Disorder and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Obsessive-Compulsive Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Obsessive-Compulsive Disorder pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Obsessive-Compulsive Disorder

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Obsessive-Compulsive Disorder Overview 7

Therapeutics Development 8

Pipeline Products for Obsessive-Compulsive Disorder-Overview 8

Pipeline Products for Obsessive-Compulsive Disorder-Comparative Analysis 9

Obsessive-Compulsive Disorder-Therapeutics under Development by Companies 10

Obsessive-Compulsive Disorder-Therapeutics under Investigation by Universities/Institutes 11

Obsessive-Compulsive Disorder-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Obsessive-Compulsive Disorder-Products under Development by Companies 16

Obsessive-Compulsive Disorder-Products under Investigation by Universities/Institutes 17

Obsessive-Compulsive Disorder-Companies Involved in Therapeutics Development 18

AbbVie Inc. 18

Addex Therapeutics Ltd 19

C4X Discovery Ltd 20

F. Hoffmann-La Roche Ltd. 21

Heptares Therapeutics Ltd. 22

Novartis AG 23

Omeros Corporation 24

Rottapharm SpA 25

Sellas Inc. 26

Obsessive-Compulsive Disorder-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 33

Drug Profiles 34

ADX-71743-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

ADX-88178-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

bitopertin-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

CR-5542 Series-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

CR-5772 Series-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

dipraglurant IR-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

fluvoxamine maleate-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

mavoglurant-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

methoxycoronaridine-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

OMS-527-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Small Molecules to Inhibit DAT and SERT for CNS Disorders-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

zolpidem tartrate-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Obsessive-Compulsive Disorder-Recent Pipeline Updates 51

Obsessive-Compulsive Disorder-Dormant Projects 57

Obsessive-Compulsive Disorder-Discontinued Products 58

Obsessive-Compulsive Disorder-Product Development Milestones 59

Featured News & Press Releases 59

Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 59

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 61

Disclaimer 61

List of Tables

Number of Products under Development for Obsessive-Compulsive Disorder, H1 2015 8

Number of Products under Development for Obsessive-Compulsive Disorder-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Comparative Analysis by Unknown Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Investigation by Universities/Institutes, H1 2015 17

Obsessive-Compulsive Disorder-Pipeline by AbbVie Inc., H1 2015 18

Obsessive-Compulsive Disorder-Pipeline by Addex Therapeutics Ltd, H1 2015 19

Obsessive-Compulsive Disorder-Pipeline by C4X Discovery Ltd, H1 2015 20

Obsessive-Compulsive Disorder-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 21

Obsessive-Compulsive Disorder-Pipeline by Heptares Therapeutics Ltd., H1 2015 22

Obsessive-Compulsive Disorder-Pipeline by Novartis AG, H1 2015 23

Obsessive-Compulsive Disorder-Pipeline by Omeros Corporation, H1 2015 24

Obsessive-Compulsive Disorder-Pipeline by Rottapharm SpA, H1 2015 25

Obsessive-Compulsive Disorder-Pipeline by Sellas Inc., H1 2015 26

Assessment by Monotherapy Products, H1 2015 27

Number of Products by Stage and Target, H1 2015 29

Number of Products by Stage and Mechanism of Action, H1 2015 31

Number of Products by Stage and Route of Administration, H1 2015 32

Number of Products by Stage and Molecule Type, H1 2015 33

Obsessive-Compulsive Disorder Therapeutics-Recent Pipeline Updates, H1 2015 51

Obsessive-Compulsive Disorder-Dormant Projects, H1 2015 57

Obsessive-Compulsive Disorder-Discontinued Products, H1 2015 58

List of Figures

Number of Products under Development for Obsessive-Compulsive Disorder, H1 2015 8

Number of Products under Development for Obsessive-Compulsive Disorder-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 27

Number of Products by Top 10 Targets, H1 2015 28

Number of Products by Stage and Top 10 Targets, H1 2015 29

Number of Products by Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 31

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

AbbVie Inc.

Addex Therapeutics Ltd

C4X Discovery Ltd

F. Hoffmann-La Roche Ltd.

Heptares Therapeutics Ltd.

Novartis AG

Omeros Corporation

Rottapharm SpA

Sellas Inc.

Obsessive-Compulsive Disorder Therapeutic Products under Development, Key Players in Obsessive-Compulsive Disorder Therapeutics, Obsessive-Compulsive Disorder Pipeline Overview, Obsessive-Compulsive Disorder Pipeline, Obsessive-Compulsive Disorder Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]